Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML

OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial –– 96% CRc in newly ...
ascopubs.org

Real-World Outcomes of Hypomethylating Agents and Venetoclax Combination Therapy in AML and Myelodysplastic Syndrome in Pakistan

The combination of venetoclax (VEN) and a hypomethylating agent (HMA) is a standard of care for patients with AML and higher-risk myelodysplastic syndromes (MDS). However, real-world outcomes data ...
Healio

VIDEO: Weaving older, newer agents into clinical practice for AML

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. I used most of these agents in practice in ...

FDA-approved oral AML therapy could let older patients avoid monthly infusion visits

The ASCERTAIN V clinical trial demonstrated that an all-oral drug combination for older patients with acute myeloid leukemia ...
Healio

VIDEO: Triple therapy regimens being explored for acute myeloid leukemia

So now, you know, we have competing standards of care in the frontline for AML, which is either high intensity induction or ...